Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
Top Cited Papers
Open Access
- 26 April 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (5), 1286-1296
- https://doi.org/10.1002/hep.20170
Abstract
Administration of a methionine and choline deficient (MCD) diet to rodents causes progressive fibrosing steatohepatitis pathologically similar to human metabolic steatohepatitis. We have previously shown that the peroxisome proliferator-activated receptor-α (PPARα) agonist, Wy-14,643, prevented the development of MCD diet-induced steatohepatitis. We have now tested whether Wy-14,643 ameliorates established steatohepatitis and fibrosis. Male C57BL6 mice were fed the MCD diet for 51 days to induce severe steatohepatitis. They were then treated with Wy-14,643 together with the MCD diet for 5 or 12 days; positive controls continued on the MCD diet for 5 or 12 days. After 5 days of Wy-14,643 treatment, alanine aminotransferase (ALT) levels were significantly decreased, steatohepatitis less severe, and hepatic lipoperoxides significantly reduced. After 12 days, hepatic triglycerides were normalized and there was near resolution of histological changes. MCD dietary feeding was associated with increased expression of vascular cell adhesion molecule (VCAM)-1, and increased numbers of activated macrophages in the liver. Treatment with Wy-14,643 reduced VCAM-1 expression and macrophage numbers. MCD diet-fed mice developed hepatic fibrosis with increased hepatic collagen α1(I), tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, and matrix metalloproteinase (MMP)-13 mRNA levels. After treatment with Wy-14,643, expression of these genes was reduced in a manner that paralleled the reduction in activated hepatic stellate cells and near resolution of liver fibrosis. In conclusion, the present study shows that MCD diet-induced fibrosing steatohepatitis can be reversed by treatment with Wy-14,643. It is likely that activation of PPARα reverses fibrosis indirectly by reducing stimuli, such as lipid peroxides, and activation of cells responsible for promoting hepatic fibrosis. (Hepatology 2004;39:1286-1296.)Keywords
This publication has 48 references indexed in Scilit:
- Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in MiceHepatology, 2003
- Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinomaGastroenterology, 2002
- Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely ObeseGastroenterology, 2001
- Liver fibrosis in overweight patientsGastroenterology, 2000
- Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitisHepatology, 1998
- Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammationGastroenterology, 1996
- Reduction of the concentrations of prostaglandins E2 and F2α, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrateToxicology Letters, 1996
- Targeted Disruption of the α Isoform of the Peroxisome Proliferator-Activated Receptor Gene in Mice Results in Abolishment of the Pleiotropic Effects of Peroxisome ProliferatorsMolecular and Cellular Biology, 1995
- Nonalcoholic steatohepatitis: An expanded clinical entityGastroenterology, 1994
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 YearsHepatology, 1990